6 Matching Annotations
  1. Sep 2021
    1. while the severity of RLS did not significantly change after CBT-i treatment, both sleep quality and anxiety symptoms were improved.

      This is exactly what one would expect. Though, I'd not be surprised if there were small reductions in RLS severity over time.

  2. Aug 2021
    1. Periodic Limb Movements of Sleep measurementsconfirmedthat ULDNallowed equivalent control of limb movements at half the prior dose of D2/3 agonists. Although the naltrexone dosewas 0.15 ug, the effect was retained at 100 ug and 1 mg(Bear and Kessler, 2014a,2014b).Thus, naltrexone proved effective forRLS, putativelyby facilitating sensitization of D2/3 agonists.

      The sources are patents. 2014a and 2014b.

      It is interesting that the benefits were retained over a large dose range. Oddly, full LDN doses (when combined with benzos) can help treat tardive dyskinesia. Thus, it seems plausible that the benefits for RLS are retained at even higher doses. I've not yet checked the sources to see if higher doses were tested. That is, doses over 1 mg. I doubt they were, because it would probably have been mentioned here.

    1. ResultsImprovement (decline IRLS score >10) was significantly higher in selenium (50 and 200 μg) than placebo group.

      Not only was is significant, but it was impressive! The 200 μg dose cut the score over 50%, compared to 20-22% reductions in the placebo. Everyone with RLS should be given selenium.

      However, I disagree with the authors that this should be a replacement. Multiple treatments are likely necessary to achieve adequate relief.

    2. Selenium prescription in daily recommended dose of 50 μg

      Not sure why 50 instead of 200. Though the superiority of 200 μg was not statistically significant, I doubt there is any risk to such a dose.

  3. Feb 2020